Health Care [ 12/12 ] | Biotechnology [ 64/73 ]
NASDAQ | Common Stock
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
In addition, it develops minimal residual disease post-diagnostic tests.
The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
May 13, 25 | -3.10 | -3.99 Increased by +22.31% |
Feb 20, 25 | -2.89 | -4.97 Increased by +41.85% |
Nov 12, 24 | -3.50 | -6.43 Increased by +45.57% |
Aug 13, 24 | -51.06 | - |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Mar 31, 25 | 31.84 M Increased by +19.15% | -106.21 M Increased by +51.48% | Decreased by -333.61% Increased by +59.28% |
Dec 31, 24 | 38.25 M Increased by +26.14% | -97.07 M Decreased by -1.67 K% | Decreased by -253.75% Decreased by -1.30 K% |
Sep 30, 24 | 28.65 M Increased by +38.27% | -125.69 M Increased by +85.90% | Decreased by -438.67% Increased by +89.80% |
Jun 30, 24 | 31.97 M Increased by +42.63% | -1.59 B Decreased by -721.23% | Decreased by -4.96 K% Decreased by -475.76% |
Mar 31, 24 | 26.72 M Increased by +36.03% | -218.91 M Decreased by -13.04% | Decreased by -819.26% Increased by +16.90% |
Dec 31, 23 | 30.33 M Increased by +N/A% | -5.49 M Increased by +93.16% | Decreased by -18.12% - |
Sep 30, 23 | 20.72 M Increased by +N/A% | -891.45 M Decreased by -1.37 K% | Decreased by -4.30 K% - |
Jun 30, 23 | 22.41 M - | -193.04 M - | Decreased by -861.27% - |